High interest in Long-Acting Injectable PrEP among Filipina Transfeminine Adults

Author:

Restar Arjee JavellanaORCID,Quilantang Ma Irene,Wickersham Jeffrey,Adia Alex,Guigayoma JohnORCID,Bermudez Amiel Nazer,Galárraga Omar,Flores Dalmacio DennisORCID,Cu-Uvin Susan,Nazareno Jennifer,Operario Don,Sison OliviaORCID

Abstract

AbstractTransfeminine adults are impacted by the HIV epidemic in the Philippines, and newly approved modalities of pre-exposure prophylaxis (PrEP), including long-acting injectable (LAI-PrEP), could be beneficial for this group. We utilized secondary data from the #ParaSaAtin survey that sampled Filipina transfeminine adults (n=139) and conducted a series of multivariable logistic regressions with lasso selection to explore factors independently associated with PrEP outcomes, including awareness, discussion with trans friends, and interest in LAI-PrEP. Overall, 53% of Filipina transfeminine respondents were aware of PrEP, 39% had discussed PrEP with their trans friends, and 73% were interested in LAI-PrEP. PrEP awareness was associated with being non-Catholic, having previously been HIV tested, discussing HIV services with a provider, and having high HIV knowledge (p<0.05). Discussing PrEP with friends was associated with older age, having experienced healthcare discrimination due to transgender identity, having HIV tested, and having discussed HIV services with a provider (p<0.05). Interest in LAI-PrEP was associated with living in Central Visayas, having discussed HIV services with a provider, and having discussed HIV services with a sexual partner were associated (p<0.05). Implementing LAI-PrEP in the Philippines requires addressing systemic improvements across personal, interpersonal, social, and structural levels in healthcare access, including efforts to create healthcare settings and environments with providers who are trained and competent in transgender health and can address the social and structural drivers of trans health inequities, including HIV and barriers to LAI-PrEP.

Publisher

Cold Spring Harbor Laboratory

Reference53 articles.

1. Joint United Nations Programme on HIV/AIDS [UNAIDS]. UNAIDS Data 2021. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS Available at: https://www.unaidsorg/sites/default/files/media_asset/2020_aids-data-book_enpdf. 2021.

2. PrEPWatch A. Country Updates: Philippines 2022.

3. Health Technology Assessment Council - Philippines Department of Health. Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV infection. Available at: https://bit.ly/HTAC-ES-OralPrEP_Recomm. 2022.

4. Joint United Nations Programme on HIV/AIDS [UNAIDS]. UNAIDS Data 2019 2020.

5. Cabotegravir for HIV prevention in cisgender men and transgender women;New England Journal of Medicine,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3